Source: Annual Congress 2010 - COPD: cardiovascular comorbidities
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Stolz, K. Kostantinos, F. Blasi, J. Rakic, P. Castellotti, B. Milenkovic, W. Boersma, A. Lacoma, C. Prat, T. Welte, R. Louis, J. Aerts, A. Torres, E. Wouters, M. Tamm (Basel, Switzerland; Larissa, Greece; Milan, Italy; Belgrade, Republic Of Serbia; Breda, Maastricht, Netherlands; Badalona, Barcelona, Spain; Hannover, Germany; Liege, Belgium). Implications of cardiovascular comorbidity and serum proadrenomedullin in dyspnoea scores in stable COPD. Eur Respir J 2010; 36: Suppl. 54, 5215

Member's Comments

No comment yet.

Related content which might interest you: Burden of comorbidities and NT-proBNP concentrations in stable COPD patients Source: Annual Congress 2013 –The latest insights in respiratory muscles, neuromuscular disease and comorbidities Year: 2013 LATE-BREAKING ABSTRACT: Elevated cardiovascular risk as measured by QRISK2 score in patients hospitalized for acute COPD exacerbation versus stable COPD outpatients Source: International Congress 2014 – Comorbidities Year: 2014 Cardiovascular comorbidity in severe COPD patients Source: International Congress 2017 – Markers of COPD progression Year: 2017 Circulating copeptin is associated with mortality irrespectively of exacerbation rate in stable COPD Source: International Congress 2014 – COPD - from biomarkers to novel therapeutic opportunities Year: 2014 Impact of cardiovascular comorbidities on COPD exacerbations Source: Annual Congress 2007 - COPD and comorbidity Year: 2007 Role of comorbidities in stable COPD patients mortality Source: International Congress 2016 – Monitoring comorbidities Year: 2016 Impact of comorbidities in COPD prognosys scores Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016 Relationship between dyspnea and depression in the elderly patients with chronic obstructive pulmonary disease Source: International Congress 2014 – COPD: points to ponder Year: 2014 Does serum uric acid levels predict in-hospital mortality in severe COPD exacerbations? Source: International Congress 2015 – COPD: interesting notes Year: 2015 Pharmacological treatment of self-reported cardiovascular comorbidity in COPD patients Source: Eur Respir J 2007; 30: Suppl. 51, 453s Year: 2007 Prevalence of night-time dyspnoea in COPD and its implications for prognosis Source: Eur Respir J 2014; 43: 1590-1598 Year: 2014 Comparing the prevalence of depression and anxiety in patients admitted with an exacerbation of COPD using two scoring systems Source: International Congress 2015 – Asthma and COPD: overlap and exacerbations Year: 2015 Assessing COPD profiles and outcomes by dyspnoea severity Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Determinants of dyspnea in stable COPD patients Source: Annual Congress 2011 - COPD management Year: 2011 Cognitive dysfunction is greater in patients hospitalised with COPD exacerbations than with worsening heart failure Source: International Congress 2014 – Markers Year: 2014 Changes in cognitive status during acute exacerbation of COPD Source: International Congress 2015 – Rehabilitation, exercise, hospitalisation and COPD Year: 2015 Change in breathlessness and symptom scores during hospitalisation with exacerbations of COPD Source: Eur Respir J 2004; 24: Suppl. 48, 511s Year: 2004 Serum hyaluronidase-1 is increased in COPD exacerbations and is associated with COPD severity and outcomes Source: International Congress 2018 – Disease exacerbations from a molecular point of view Year: 2018 Impact of co-morbidities on the rehabilitation outcome in COPD patients Source: Annual Congress 2007 - Impact of comorbidities in pulmonary rehabilitation Year: 2007 Baseline self-reported comorbidity in COPD patients referred for pulmonary rehabilitation (PR) Source: Annual Congress 2006 - COPD comorbidity Year: 2006